ADAmoako Duah

Amoako Duah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amoako Duah has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lower Allele Frequency of TERT -rs2242652 in Sub-Saharan African Populations Compared With American Populations and Hepatocellular Carcinoma Risk

    by Perapa Chotiprasidhi, Viviana P. Gonzalez Umpierre, Yvonne Ayerki Nartey, Hunter B. Miller, Adrienne F. Gefre, Karina Sato-Espinoza, Daniel O'BRien, Jun Ma, Yaw Awuku, Adwoa Agyei-Nkansah, et al.

    PURPOSE: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. The higher incidence and earlier onset of HCC in sub-Saharan Africa suggest a potential role for a genetic predisposition. This study evaluated the association of TERT -rs2242652-(A), a variant linked to lower HCC risk, with HCC in populations from Ghana, Nigeria, and Cameroon, compared with a population from the United States. METHODS: The study included 537 patients with HCC: United States (n = 348), Ghana (n = 79), Nigeria (n = 43), and Cameroon (n = 67). The control group had 2,872 cancer-free individuals: United States (n = 2,399), Ghana (n = 323), Nigeria (n = 85), and Cameroon (n = 65). Whole-exome sequencing was conducted using germline DNA, and data for TERT -rs2242652 were analyzed. Odds ratios (ORs) and 95% CIs were calculated using unconditional logistic regression. Chi-square tests assessed protective allele frequencies. RESULTS: In the US cohort, TERT -rs2242652 was significantly associated with lower HCC risk (OR, 0.75 [95% CI, 0.58 to 0.96]; P = .02), with an allele frequency of 18.8% (15.4% in HCC cases v 19.3% in controls). In the combined sub-Saharan African population, no significant association was observed, but there was a trend toward decreased HCC risk (OR, 0.80 [95% CI, 0.53 to 1.22]; P = .29), with an allele frequency of 12.2% (10.6% in HCC cases v 12.9% in controls). Separate analyses of Ghanaian, Nigerian, and Cameroonian populations showed similar nonsignificant trends. The protective allele frequency in the combined African populations was significantly lower than in the US cohort ( P < .0001). CONCLUSION: In sub-Saharan African populations, there was a lower frequency of the HCC protective allele TERT -rs2242652 compared with European Americans. These findings underscore the importance of multiethnic genetic studies in understanding population differences in HCC risk and developing prevention strategies.

  • Open Access

    Risk factors, treatment outcomes and predictors of death of newly diagnosed patients with venous thromboembolism in a quaternary hospital in Ghana.

    by Amoako Duah, Yvonne A. Nartey, Kwame Ekremet

    Objective: To determine the sociodemographic characteristics, risk factors, treatment outcomes and predictors of death of newly diagnosed patients with venous thromboembolism (VTE).Design: A retrospective studySettings: University of Ghana Medical Centre (UGMC) Ltd, a 650-bed quaternary hospital located in Accra, Ghana.Participants: One hundred and eighty-six adult patients admitted with a diagnosis of deep vein thrombosis and pulmonary embolism (PE), confirmed by Computed tomography pulmonary angiography (CTPA), from January 2022 to April 2024, were included in this study. All patients with a differential diagnosis of DVT or PE for whom confirmation by Doppler USG and CTPA could not be obtained were excluded.Main outcome measure: Risk factors, treatment outcomes and predictors of death of patients diagnosed with venous thromboembolismResults: The mean age of study participants was 62.7 years (±15.5), and a slightly higher proportion were female (n=108, 58.1%). The mortality rate was 16.3%. Close to half of the patients (n=88, 47.3%) had a history of immobi-lisation as the predominant risk factor for VTE. On multivariate analysis, increasing age (OR 1.04, 95% CI 1.00-1.08), increasing urea level (OR 1.12, 95% CI 1.03 – 1.21) and presence of cancer (OR 6.02, 95% CI 0.003) remained significant predictors of mortality.Conclusion: Immobilisation was the main risk factor for VTE in this study. In-hospital mortality was relatively high, with death in 1 in 6 patients diagnosed. Patients with advanced age, high urea and malignancy should be monitored closely and early aggressive treatment instituted to reduce mortality.

  • Open Access

    Figure 1 from GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients

    by Yvonne Ayerki Nartey, Ju Dong Yang, Tyler J. Zemla, Joshua Ayawin, Shadrack Osei Asibey, Mohamed El-Kassas, Sally Afua Bampoh, Amoako Duah, Adwoa Agyei-Nkansah, Yaw Asante Awuku, et al.

    ROC of GALAD scores for the detection of HCC. X axis: specificity; Y axis: sensitivity. Sensitivity #1; controls with high AFP (>400 ng/mL), high AFP-L3% (>35%), or high DCP (>2.85 ng/mL) are imputed as cases (N = 14). Sensitivity #2; controls with high AFP (>400 ng/mL), high AFP-L3% (>35%), or high DCP.

  • Open Access

    Data from GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients

    by Yvonne Ayerki Nartey, Ju Dong Yang, Tyler J. Zemla, Joshua Ayawin, Shadrack Osei Asibey, Mohamed El-Kassas, Sally Afua Bampoh, Amoako Duah, Adwoa Agyei-Nkansah, Yaw Asante Awuku, et al.

    Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide including sub-Saharan Africa. The GALAD score, derived from Gender, Age, Lens culinaris agglutinin-reactive fraction of alpha fetoprotein, Alpha fetoprotein, and Des-carboxy-prothrombin, has high accuracy in diagnosing HCC in Asia, Europe, and North America; however, it has not been validated in an African cohort. The aim of this study was to assess the performance of the GALAD score in the diagnosis of HCC in sub-Saharan Africa. Clinical data from patients with cirrhosis (n = 93) or HCC (n = 78) from outpatient hepatology clinics at three teaching hospitals in Ghana were abstracted, and serum samples were analyzed. A logistic regression model predicting HCC status based on the GALAD score was constructed to obtain the ROC curve for GALAD. The AUC with 95% confidence interval (CI) was calculated. The median GALAD score was higher among patients with HCC versus cirrhosis controls (8.0 vs. −4.1, P < 0.01). The AUC of the GALAD score for HCC detection was 0.86 (95% CI, 0.79–0.92). At a cut-off value of −0.37, the GALAD score had a sensitivity of 0.81 and a specificity of 0.86. The AUC (95% CI) was 0.87 (0.80–0.95) and 0.81 (0.67–0.94) in hepatitis B virus–positive and hepatitis B virus–negative patients, respectively. The GALAD score has a high accuracy for HCC detection. It has great potential to improve HCC surveillance in sub-Saharan Africa where imaging resources are limited.Significance:The GALAD score or its relevant modifications have the potential to aid in improving HCC surveillance efforts in low-resource settings in sub-Saharan Africa. This could enhance early detection rates of HCC and potentially improve survival rates in resource-limited settings.

  • Open Access

    Table 2 from GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients

    by Yvonne Ayerki Nartey, Ju Dong Yang, Tyler J. Zemla, Joshua Ayawin, Shadrack Osei Asibey, Mohamed El-Kassas, Sally Afua Bampoh, Amoako Duah, Adwoa Agyei-Nkansah, Yaw Asante Awuku, et al.

    Optimal cut-off of the GALAD score with sensitivity and specificity

  • Open Access

    Table 5 from GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients

    by Yvonne Ayerki Nartey, Ju Dong Yang, Tyler J. Zemla, Joshua Ayawin, Shadrack Osei Asibey, Mohamed El-Kassas, Sally Afua Bampoh, Amoako Duah, Adwoa Agyei-Nkansah, Yaw Asante Awuku, et al.

    Comparison of the AUC of the three different GALAD score models

  • Open Access

    Table 1 from GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients

    by Yvonne Ayerki Nartey, Ju Dong Yang, Tyler J. Zemla, Joshua Ayawin, Shadrack Osei Asibey, Mohamed El-Kassas, Sally Afua Bampoh, Amoako Duah, Adwoa Agyei-Nkansah, Yaw Asante Awuku, et al.

    Clinical characteristics of Ghanaian cirrhosis and HCC cohort

  • Open Access

    Table 3 from GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients

    by Yvonne Ayerki Nartey, Ju Dong Yang, Tyler J. Zemla, Joshua Ayawin, Shadrack Osei Asibey, Mohamed El-Kassas, Sally Afua Bampoh, Amoako Duah, Adwoa Agyei-Nkansah, Yaw Asante Awuku, et al.

    Refit of the logistic regression model

  • Open Access

    Table 4 from GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients

    by Yvonne Ayerki Nartey, Ju Dong Yang, Tyler J. Zemla, Joshua Ayawin, Shadrack Osei Asibey, Mohamed El-Kassas, Sally Afua Bampoh, Amoako Duah, Adwoa Agyei-Nkansah, Yaw Asante Awuku, et al.

    Refit of the logistic regression model using the backward selection process

  • Open Access

    GALAD Score for the Diagnosis of Hepatocellular Carcinoma in Sub-Saharan Africa: A Validation Study in Ghanaian Patients

    by Yvonne Ayerki Nartey, Ju Dong Yang, Tyler J. Zemla, Joshua Ayawin, Shadrack Osei Asibey, Mohamed El-Kassas, Sally Afua Bampoh, Amoako Duah, Adwoa Agyei-Nkansah, Yaw Asante Awuku, et al.

    Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide including sub-Saharan Africa. The GALAD score, derived from Gender, Age, Lens culinaris agglutinin-reactive fraction of alpha fetoprotein, Alpha fetoprotein, and Des-carboxy-prothrombin, has high accuracy in diagnosing HCC in Asia, Europe, and North America; however, it has not been validated in an African cohort. The aim of this study was to assess the performance of the GALAD score in the diagnosis of HCC in sub-Saharan Africa. Clinical data from patients with cirrhosis (n = 93) or HCC (n = 78) from outpatient hepatology clinics at three teaching hospitals in Ghana were abstracted, and serum samples were analyzed. A logistic regression model predicting HCC status based on the GALAD score was constructed to obtain the ROC curve for GALAD. The AUC with 95% confidence interval (CI) was calculated. The median GALAD score was higher among patients with HCC versus cirrhosis controls (8.0 vs. −4.1, P < 0.01). The AUC of the GALAD score for HCC detection was 0.86 (95% CI, 0.79–0.92). At a cut-off value of −0.37, the GALAD score had a sensitivity of 0.81 and a specificity of 0.86. The AUC (95% CI) was 0.87 (0.80–0.95) and 0.81 (0.67–0.94) in hepatitis B virus–positive and hepatitis B virus–negative patients, respectively. The GALAD score has a high accuracy for HCC detection. It has great potential to improve HCC surveillance in sub-Saharan Africa where imaging resources are limited. Significance: The GALAD score or its relevant modifications have the potential to aid in improving HCC surveillance efforts in low-resource settings in sub-Saharan Africa. This could enhance early detection rates of HCC and potentially improve survival rates in resource-limited settings.